Exhibitor & Exhibit Information of the Third China International Import Expo
General No. 16
Medical Equipment & Healthcare Products (No.3)
Notice for Reading

Dear readers and users of the *Exhibitor and Exhibit Information of the Third China International Import Expo*,

On the basis that exhibitors volunteer to provide relevant information, the China International Import Expo Bureau (hereinafter referred to as the "CIIE Bureau") compiles, not for profit, and freely provides the *Exhibitor and Exhibit Information of the Third China International Import Expo (CIIE)* (hereinafter referred to the *Exhibitor and Exhibit Information*) in order to timely provide buyers and relevant units with information about the exhibitors and their exhibits and facilitate the matchmaking and negotiation before the CIIE.

The information on relevant exhibitors, their commodities or services has been provided by corresponding exhibitors of the third CIIE. Meanwhile, such exhibitors will be liable for the truthfulness, accuracy, and validity of what they have provided. The CIIE Bureau just collects, arranges, and releases relevant information.

When you read or use the *Exhibitor and Exhibit Information*, please contact the CIIE Bureau timely if any untruthful or unfaithful information is found, for prompt verification and correction. If any suspected illegal condition is found, relevant legal provisions can be referred to for disposal or please immediately contact the CIIE Bureau and we will remind relevant units for rectification.

It is hereby declared.

Contact: zsc@ciie.org

China International Import Expo Bureau
June, 2020
Contents

Introduction to Exhibition Area .............................................. 1

Novartis ............................................................................. 3

ZOLL Medical ..................................................................... 8

VYAIRE MEDICAL ............................................................. 13

Boston Scientific ................................................................. 25

Eli Lilly ................................................................................ 30
Introduction to Exhibition Area

Focusing on people's desire for a better life and their pursuit of a healthy life, the Exhibition Area of Medical Equipment & Healthcare Products integrates the whole industrial chain of "massive health" to create a platform for the first-time release of "massive health" products and technologies featuring high-tech intelligence, targeted personalization, standard specialization, and internationalization. Exhibitors and buyers have access to the authoritative interpretation of new industrial policies and regulations through high-quality supporting activities co-organized by industry authorities.

Exhibition items and services include: drugs, medical devices, public health and epidemic prevention products, old-age rehabilitation and ancillary products, dietary supplements, health care, medical cosmetology, health tourism, health care products, etc.

The exhibition area focuses on creating a theme specializing in "public health and epidemic prevention" so as to display internationally advanced public health and epidemic
prevention products, technologies, services and key products that play an important role in the COVID-19 prevention and control in a centralized manner, and further to promote the balancing of market supply and demand and exchanges and popularity of the public health and epidemic prevention related frontier research and application, facilitate the sustainable development of the industry, strengthen people's awareness of public health, and contribute to the building, improvement, optimization and innovation of the global public health system.
Novartis

◆ Brief Introduction to Exhibitors

Based in Switzerland, Novartis is an enterprise specialized in medical and health products. It has participated in the First and Second CIIE. With innovative science and digital technology, Novartis makes its CAR-T cell therapy and gene therapy the first approved products of the same type in the world. Novartis has about 109,000 employees from more than 140 countries and regions around the world. The business of Novartis in China includes Novartis Oncology, Novartis Pharmaceuticals and Sandoz. With two major production bases and R&D facilities in Beijing, Shanghai and Jiangsu, Novartis serves the health of Chinese consumers with a portfolio of diversified businesses from R&D to production and sales.

Official Website: https://www.novartis.com

https://www.novartis.com.cn

Contact Person: Tang Jie

Contact: jie.tang@novartis.com

◆ Highlights

Entresto® (Sacubitril Valsartan Sodium Tablets)
It is a groundbreaking drug in the field of chronic heart failure. It can be used for adult patients with chronic heart failure (NYHA II-IV, LVEF \( \leq 40\% \)) with reduced ejection fraction. It can reduce the risk of cardiovascular death and heart failure hospitalization. It can replace angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) and can be used in combination with other heart failure treatment drugs. It was listed in 2017 and included in national medical insurance in 2019.

![Picture 1: Product Diagram of Entresto® (Sacubitril Valsartan Sodium Tablets)](image_url)

**Cosentyx® (Secukinumab)**

It is the world's first and only fully-human IL-17A inhibitor. It has been approved for marketing in many countries and regions for the treatment of psoriasis, ankylosing spondylitis and psoriatic arthritis. In 2019, it was approved in China for the treatment of adult patients with moderate to severe plaque psoriasis in line with the indications of systemic therapy or phototherapy. In 2020, it was approved to treat the
second indication of ankylosing spondylitis. It is the first and only interleukin inhibitor approved to treat ankylosing spondylitis in China.

Picture 2: Product Diagram of Cosentyx® (Secukinumab)

Revolade® (Eltrombopag Olamine Tablets)

It is a TPO receptor agonist for the treatment of idiopathic immune thrombocytopenic purpura (ITP) at the age of 12 and above. It can increase the platelet counts within 1 to 2 weeks and reduce the risk of bleeding by 65%. It can maintain the long-term response rate of 86% and the platelet count of > 50x10⁹ / L, and promote the reconstruction of immunological balance. About 30% of patients can achieve sustained response after drug withdrawal. Its safety is equivalent to that of the placebo without any new adverse
reactions. It has non-peptide innovative small molecules with no immunogenicity, convenient oral administration, economic medical insurance and flexible dosage adjustment. It can alleviate fatigue symptoms of patients. It is the second-line preferred treatment for ITP recommended by authoritative guidelines at home and abroad (2019 ASH, 2019 ICR, 2018 China ITP diagnosis and treatment guidelines).

**TAFINLAR® (Dabrafenib Mesylate Capsules) + Mekinist® (Trametinib Tablets)**

In December 2019, it entered China's market for double target treatment of melanoma. Tafinlar® (dalafeni mesylate capsules) is a powerful and selective inhibitor of BRAF kinase activity. Mekinist® (trimetinib tablets) is a reversible, highly selective allosteric inhibitor of MEK1 and MEK2 kinase activity. The combination of the two drugs can inhibit the two targets of BRAF and MEK at the same time, so that the focus can be alleviated rapidly and significantly. And it can treat unresectable or metastatic melanoma with positive BRAF V600 mutation, and realize adjuvant treatment after complete removal of stage III melanoma with positive BRAF V600 mutation. Clinical research shows that the combination of the two drugs can help patients with advanced BRAF V600 mutant melanoma to achieve higher disease relief and longer progression-free survival, as well as reduce the risk of postoperative
recurrence. The relapse-free survival rate is as high as 54% within 4 years.

![Picture 4: Product Diagram of TAFINLAR® (Dabrafenib Mesylate Capsules) + Mekinist® (Trametinib Tablets)](image)

**Zykadia® (Ceritinib Capsules)**

It is the first second-generation of ALK inhibitor that works on brain lesions through the blood-brain barrier. It is suitable for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed after the treatment of crizotinib or who are resistant to crizotinib and who are positive for anaplastic lymphoma kinase (ALK). It has a rapid onset and a median response time of 6.1 weeks. It has a good effect on patients with crizotinib resistance or intolerance and has a good effect in different drug resistance mechanisms. In studies, the median OS was treated with sequential crizotinib for more than seven years.

![Picture 5: Product Diagram of Zykadia® (Ceritinib Capsules)](image)
ZOLL Medical

◆ Brief Introduction to Exhibitors

Founded in 1980 and based in Massachusetts, ZOLL Medical (USA) specializes in the development and sale of medical equipment and software solutions. The business of it covers defibrillation and monitoring, circulatory and CPR feedback, data management, fluid resuscitation and therapeutic body temperature control. The company focuses on the field of emergency recovery, with a large number of patents and emerging technologies. The business in China covers in-hospital care, pre-hospital care and public care.

Official Website: https://www.zoll.com/

Contact Person: Zhang Yunhe/ Liu Deting

Contact: 13916748311/18621902127

◆ Highlights

AED plus Automatic External Defibrillator

Using Zoll's patented low-energy two-way square wave technology and compression feedback technology, it devotes itself to helping out-of-hospital cardiac arrest patients improve their survival rate. The equipment enjoys some special designs such as airway opening support,
voice prompt during the whole process, integrated electrode piece and so on. It can be used to help non-professional rescuers to carry out first aid.

Picture 6: Product Diagram of AED Plus Automatic External Defibrillator

**X Series® Defibrillation Monitor**

Adopting a new design concept, it integrates the functional characteristics of a defibrillator, high-end monitor, electrocardiograph and non-invasive percutaneous temporary pacemaker. It is a defibrillator and defibrillation monitoring resuscitation system for emergency personnel to improve patient safety and the rate of emergency treatment.

Picture 7: Product Diagram of X Series® Defibrillation Monitor
AutoPulse® Automatic CPR (Cardiopulmonary Resuscitation) System

As automatic CPR equipment, it can be operated in occasions such as stairs, narrow corners and elevators to ensure that patients can always get high-quality CPR without worrying about unnecessary interruption caused by factors such as the patient's body tilt and emergency personnel's alternation. It is driven by electric power with quality of easy using and carrying. The advantage of whole chest compression mode can reduce the risk of sternum injuries. It has good X-ray compliance and is suitable for the environment such as a catheterization room where artificial CPR cannot be achieved. Compared with manual CPR, it can provide high-quality CPR in a hospital environment, catheter intervention operation environment and a variety of transport environments.

Picture 8: Product Diagram of AutoPulse® Automatic CPR (Cardiopulmonary Resuscitation) System
EMV+ Emergency-Transport Ventilator

The interface is intuitive and easy to operate. It contains operation modes that can provide intubation or non-invasive treatment for infants and adults. It can also provide continuous positive pressure ventilation support for patients with acute and chronic respiratory failure, and can be used in the MRI room. It has intelligent help information to assist the operator to remove the alarm from the patient and the machine. Small, portable and durable, it is suitable for transportation in and out of the hospital and other severe environments.

![Product Diagram of EMV+ Emergency-Transport Ventilator](image)

R Series Defibrillation Monitor

With Real CPR Hel technology, it can guide the rescue personnel to perform CPR with correct depth, speed, release operation and the shortest pause time. The product is specially designed with children's dual feedback probe system, which can provide CPR support for patients under 8 years old. In combination with the RescueNet Code Review, it can review and analyze the electronic emergency documents and CPR
quality data, and improve the emergency response of patients with cardiac arrest.

Picture 10: Product Diagram of R Series Defibrillation Monitor
VYAIRED MEDICAL

◆ Brief Introduction to Exhibitors

Founded in 2016, Vyaire Medical is mainly engaged in respiratory system related products, providing products in four fields including respiratory diagnosis, mechanical ventilation, airway management and operating room consumables. Its products include "VIASYS" ventilator, "SUNDIS" and "JAEGGER" lung function detector, as well as "BellaVista" and "FABIAN" series ventilator products from Switzerland. At present, the company operates more than 27,000 kinds of respiratory products, including respiratory diagnostic units, ventilators, pulmonary function equipment, airway management and surgical nursing consumables, which are used in various stages of diagnosis, treatment, and monitoring of respiratory diseases. The main products in China include ventilators, pulmonary function instruments and respiratory-related consumables.

Official Website: https://www.vyaire.com

Contact Person: Zhao Chao

Contact: wallis.zhao@vyaire.com

◆ Highlights

Bellavista 1000 Ventilator
It is an intelligent ventilator for invasive ventilation, noninvasive ventilation and transport environment, suitable for breathing-support ventilation for newborns, children and adults, and also for transport environment. It has the characteristic functions of lung recruitment under one-click, esophageal pressure monitoring, intelligent dynamic lung, ventilation summary, AVM adaptive ventilation and so on.

![Product Diagram of Bellavista 1000 Ventilator](image)

Picture 11: Product Diagram of Bellavista 1000 Ventilator

**Vyntus ONE+BODY Pulmonary Function Product**

It is a pulmonary function test system that can provide a complete clinical pulmonary function diagnosis scheme, including routine ventilation function, diffusion function, residual gas function, and airway resistance.
Vyntus CPX Pulmonary Function Products

This is a cardiopulmonary exercise testing system suitable for sports medicine and rehabilitation medicine. It can provide accurate diagnosis data and ensure the safety of the subjects at the same time.
FABIAN HFO Neonatal Ventilator (High Frequency)

It is suitable for mechanical ventilation of premature infants, newborns and infants, including functions of non-invasive ventilation, constant frequency ventilation, high-frequency ventilation.

Picture 14: Product Diagram of FABIAN HFO Neonatal Ventilator (High Frequency)

Intelligent Hospital Solutions Medical IoT Platform

Collection and analysis of ventilator data are realized through data display records, abnormal alarms, statistical analysis to assist the clinical management of the data network collection and analysis platform for the usage of the ventilator.
VELA Ventilator

It is a multi-functional ventilator which is suitable for children's and adults' mechanical ventilation, and out-of-hospital transport ventilation, integrating invasive and noninvasive ventilation.

MS PFT+BODY Pulmonary Function Products

These form a widely used clinical pulmonary function test system with thousands of devices in use in China.
Fabian +nCPAP evolution Neonatal / Pediatric Ventilator
(Constant Frequency)

It is suitable for mechanical ventilation of premature infants, newborns and infants, including functions of non-invasive ventilation, and constant frequency ventilation.
**MS CPX Pulmonary Function Product**

This is a sports cardiopulmonary testing equipment, hundreds of which have been served in major domestic hospitals and scientific research institutions.

![Picture 19: Product Diagram of MS CPX Pulmonary Function Product](image)

**Fabian Therapy evolution Neonatal / Pediatric Ventilator (Noninvasive)**

It is suitable for mechanical ventilation of premature infants, newborns and infants, including functions of non-invasive ventilation, and high flow oxygen therapy.
MS PNEUMO Pulmonary Function Products

It is a primary pulmonary function test system widely used in clinical screening and scientific research.

Infant flow SIPAP Infant Ventilator

It is suitable for mechanical ventilation of premature infants,
newborns and infants, including nCPAP, dual-level mode and backup ventilation mode. It is equipped with a professional infant flow LP non-invasive generator, which can minimize the respiratory work.

Picture 22: Product Diagram of Infant flow SIPAP Infant Ventilator

**MicroLab Pulmonary Function Product**

It is widely used in physical examinations and clinical screenings with high cost performance and easiness to carry.

Picture 23: Product Diagram of MicroLab Pulmonary Function Product
**AVEA Ventilator**

It is suitable for mechanical ventilation in the fields of adults, children and newborns. It has the functions of Bicore cross lung pressure monitoring module, helium-oxygen ventilation, closed-loop control ventilation, Pflex lung recruitment tool, VCO2, etc.

![Picture 24: Product Diagram of AVEA Ventilator](image)

**3100A High-Frequency Oscillatory Ventilator**

It has passed through the authentication of FDA and can meet the needs of children under 35kg.
3100B High-Frequency Oscillatory Ventilator

It has passed through the authentication of FDA and can be used for adult respiratory support.

Blender Air Oxygen Mixer

With accurate and stable oxygen concentration control and long
service life, it can meet the most basic mixed oxygen demand of the ward.

Picture 27: Product Diagram of Blender Air Oxygen Mixer
Boston Scientific

◆ Brief Introduction to Exhibitors

Founded in June 1979, Boston Scientific is headquartered in Massachusetts, USA. It ranked among the Fortune 500 companies in succession from 2004 to 2019 and has participated in the Second CIIE. At present, the company has more than 13,000 products that can improve the quality of life, covering the fields of cardiac intervention, peripheral and tumor intervention, cardiac rhythm management and electrophysiology, endoscopic intervention, neural regulation and urinary and pelvic health. It has already obtained more than 19,000 authorized patents worldwide. It has operations in more than 120 countries and regions around the world with about 32,000 employees. Boston Scientific has officially entered China's market since 1997. The core business covers cardiac intervention, structural heart disease, cardiac rhythm management and electrophysiology, peripheral and tumor intervention, endoscopic intervention, urinary and pelvic health, and respiratory products. With Shanghai as its headquarters in Greater China, it has branches in Beijing, Guangzhou, Chengdu, Hong Kong and Taiwan with a total of about 1,300 employees.

Official Website: http://www.bostonscientific.cn/
Contact Person: Peng Kaifeng
Contact: michelle.peng@bsci.com

◆ **Highlights**

**EXALT MODEL D Disposable Duodenoscope**

For endoscopic retrograde cholangiopancreatography, it is the first single-use (one-time) duodenoscope approved by the FDA and awarded the "Breakthrough Medical Device Certification". The product is designed to replace the reused duodenoscope, so that doctors can use new sterile equipment in each operation and reduce the risk of cross infection of patients.

Picture 28: Product Diagram of EXALT MODEL D Disposable Duodenoscope

**Eluvia Nitinol Paclitaxel Eluting Vascular Stent**

It is a drug stent applied for slow-release technology of paclitaxel drug for lower extremity artery occlusion. Most of the drugs are delivered to the tissues by polymer and the downstream particles are minimized, so
as to achieve the optimal vascular recanalization rate with the lowest drug
dose on the market.

![Product Diagram of Eluvia Nitinol Paclitaxel Eluting Vascular Stent](Image)

**Picture 29: Product Diagram of Eluvia Nitinol Paclitaxel Eluting Vascular Stent**

**Rezum Steam Hyperthermia Equipment**

It uses steam heat to rapidly reduce the volume of prostate and improve related symptoms such as dysuria. The average operation time is 8 minutes. It is suitable for daytime operation in outpatient and community hospitals. With the advantages of the short operation time, fast recovery and high safety, it can reduce the disease burden of middle-aged and old patients with BPH.

![Product Diagram of Rezum Steam Hyperthermia Equipment](Image)

**Picture 30: Product Diagram of Rezum Steam Hyperthermia Equipment**
**WATCHMAN Flex Left Atrial Appendage Occlusion Device**

It is a newly designed left atrial appendage occlusion device that can simultaneously use the push method and the de-sheathing method to release the occlusion device. It enables the operator to have better control and selectivity under various complex shapes of atrial appendages. It has a unique anatomical structure of the left atrial appendage and rapid endothelialization to reduce the risk of bleeding caused by taking anticoagulant drugs.

![Product Diagram of WATCHMAN Flex Left Atrial Appendage Occlusion Device](image)

**IntellaNav MiFi Open-Irrigated Ablation Catheter Saline**

**Perfusion Ablation Catheter with Magnetic Positioning Microelectrode**

It is a disposable radiofrequency ablation catheter with the characteristics of double internal and external circulation and full head cooling. It provides a cooling effect for cardiac electrophysiological
radiofrequency ablation surgery and improves the transmural property of ablation damage. The MiFi microelectrode at the head end can provide accurate potential signals during electrophysiological radiofrequency ablation surgery, helping doctors quickly find the target location.

Picture 32: Product Diagram of IntellaNav MiFi Open-Irrigated Ablation Catheter Saline Perfusion Ablation Catheter with Magnetic Positioning Microelectrode
Eli Lilly

**Brief Introduction to Exhibitors**

Founded in 1876, Eli Lilly is based in Indiana, USA. It has participated in the Second CIIE. The products involve fields such as cardiovascular system, diabetes, oncology, immunity, central nervous system, and pain, marketing in 120 countries and regions around the world. Clinical trial research is spread in more than 50 countries and regions with drug production bases in 8 countries. Eli Lilly China is the second largest branch of Eli Lilly in the world with operations in nearly 400 cities in China. Currently, it has a factory in Suzhou engaging in the production of insulin and central nervous system drugs.

Official Website: https://www.lilly.com/

https://www.lillychina.com/

Contact Person: Xu Lujing/Duan Wuning

Contact: 8621-23020957/8621-23021366

**Highlights**

**LY-CoV555**

On March 12, 2020, Eli Lilly and AbCellera announced an agreement to jointly develop antibodies to treat and prevent 2019 new
coronavirus pneumonia (COVID-19). By this collaboration, they utilized the rapid epidemic response platform, which was developed by AbCellera under the DARPA Disease Pandemic Prevention Platform (P3) project, cooperating with Eli Lilly on its global development, production and distribution capabilities for therapeutic antibodies. On June 1, Eli Lilly announced that the first batch of patients had participated in the first phase of clinical trials of LY-CoV555.

**Baricitinib Tablets**

On April 10, 2020, Eli Lilly announced an agreement with the National Institute of Allergy and Infectious Diseases (NIAID) affiliated with the National Institutes of Health (NIH) to select Baricitinib as a part of NIAID’s adaptation research for the COVID-19. In this research, Baricitinib, as a potential therapeutic drug, would be validated on its efficacy and safety in COVID-19 inpatients. The trial was launched in the United States in early April and there were plans to extend it to Europe and Asia.

**Anti-Angiopoietin 2**

On April 10, 2020, Eli Lilly announced the promotion of LY3127804, a Lilly-developed monoclonal antibody drug for Angiopoietin 2 (Ang2), to undergo a phase 2 clinical trial for inpatients
diagnosed with COVID-19 and accompanied by high risk of acute respiratory distress syndrome (ARDS). Ang2 level will increase in ARDS patients. Eli Lilly will test whether the inhibition of Ang2 with monoclonal antibody can slow the progression of ARDS or reduce the need for mechanical ventilation in COVID-19 patients.

**Eli Lilly and TopAlliance jointly develop a potential prophylactic and therapeutic antibody therapy for COVID-19**

On May 4, 2020, Eli Lilly and TopAlliance announced an agreement to jointly develop a potential prophylactic and therapeutic antibody therapy for COVID-19 caused by the new SARS-CoV-2 coronavirus. Several neutralizing antibodies had been engineered and lead antibodies were scheduled to enter the clinical phase in the second quarter of this year.

**Forward-looking statements:**

The forward-looking statements are defined in the *U.S. Private Securities Litigation Reform Act of 1995* that reflect the above-mentioned products’ status as potential drugs to treat COVID-19 patients and Eli Lilly's current confidence in it. However, there are many risks and uncertainties in the process of drug development and commercialization. Furthermore, there is no guarantee that these products will be proven
effective in the treatment of COVID-19. Further discussion, other risks and uncertainties of these products could cause actual results to differ from Lilly's expectations. For this, please refer to the latest version of Eli Lilly's 10-K and 10-Q information sheets submitted by the American Stock Exchange. Eli Lilly assumes no obligation to update the forward-looking statements.
Official Website of the CIIE:
https://www.ciie.org/
Service hotline:
+86-21-968888

We are looking forward to seeing you at the third CIIE.